

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



BDP9066

Item No. 26264


CAS Registry No.: 2226507-04-4

Formal Name: (6S)-8-[3-(4-pyrimidinyl)-1H-

pyrrolo[2,3-b]pyridin-4-yl]-1,8-

diazaspiro[5.5]undecane

MF: $C_{20}H_{24}N_{6}$ FW: 348.4 **Purity:** ≥98% Supplied as: A solid Storage: -20°C Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BDP9066 is supplied as a solid. A stock solution may be made by dissolving the BDP9066 in the solvent of choice, which should be purged with an inert gas. BDP9066 is sparingly soluble (1-10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in acetonitrile.

BDP9066 is slightly soluble (0.1-1 mg/ml) in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

BDP9066 is an inhibitor of Cdc42-binding kinase α (MRCK α) and MRCK β (K,s = 0.0136 and 0.0233 nM, respectively).¹ It is selective for MRCKα and MRCKβ over Rho-associated kinase 1 (ROCK1) and ROCK2 (K_is = 18.4 and 5.38 nM, respectively) and a panel of 115 additional kinases at 1 μM. BDP9066 has antiproliferative activity against a panel of 757 cancer cell lines (EC₅₀s = <10 μ M). It inhibits the phosphorylation of myosin light-chain 2 (MLC2) in SCC-12 squamous cell carcinoma cells (EC₅₀ = 64 nM) and inhibits the motility of the same cells. BDP9066 (25 µg/animal) decreases average papilloma volume in a mouse two-stage model of skin carcinogenesis initiated by 7,12-dimethylbenz[a]anthracene (DMBA; Item No. 30383) and promoted by phorbol 12-myristate 13-acetate (TPA; Item No. 10008014).

Reference

1. Unbekandt, M., Belshaw, S., Bower, J., et al. Discovery of potent and selective MRCK inhibitors with therapeutic effect on skin cancer. Cancer Res. 78(8), 2096-2114 (2018).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the material can be found on our website.

Copyright Cayman Chemical Company, 10/08/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM